To detect the silent pulmonary thromboembolism (SPTE) frequency in patients who underwent craniotomy for a brain tumor, and to examine the correlation based on the data obtained from patients. Overall, 100 patients with brain tumors were included in the study. The mean age was 54.29 years (±12.5 years), with the youngest patient being 19 years old and the oldest 73 years. All patients underwent craniotomy, and a pulmonary ventilation-perfusion scintigraphy was performed 48 h after surgery to detect SPTE. The frequency of SPTE and the conditions related to it were investigated. The incidence of SPTE was 26% in patients with a brain tumor who underwent craniotomy. Statistically, no correlation was observed between SPTE and data obtained from patients (tumor histopathology, tumor localization, perilesional edema, midline shift, bleeding time, surgical positioning, smoking history, age, duration of surgery, etc.). Our study revealed a high rate of SPTE in patients with a brain tumor who underwent craniotomy. Although most articles suggest using anticoagulant therapy in these patients, the literature lacks definite evidence for the same.
Purpose: Today, stereotactic surgery (SRS) is among the treatment options for many intracranial lesions including vascular pathologies. One of the most common late complications of SRS is perilesional edema which can be treated with steroids. In addition to steroids, some new medical therapies are being investigated and one of the promising one is Bevacizumab; a monoclonal antibody against vascular endothelial growth factor (VEGF). In the cases of steroid resistant perilesional edemas, however bevacizumab has a late term effect resolution of symptoms and radiological improvement can be seen as late as more than 1,5 years after its initiation. Materials and Methods: We present a 41-year old male patient who was admitted to our clinic with epileptic seizures, headaches and hemiparesis 14 months after SRS treatment for a left fronto-parietal Spetzler-Martin Grade III arteriovenous malformation (AVM). On his first-year follow-up perilesional edema was observed for which the patient received steroid treatment, but the patient did not show any benefit from it. In the cases of steroid resistant perilesional edemas, bevacizumab can be used for reducing symptoms and even radiological perilesional edema as well. Results: In our case, we have seen the effect of bevacizumab for symptomatic perilesional edema in a AVM patient after SRS treatment after radiological / neurological recovery. Our patient's headaches decreased rapidly after 2 days after treatment and was able to mobilize himself after 2 months but total resolution of symptoms and radiological findings observed after 1,5 years. Conclusions: The duration and optimum dose of bevacizumab therapy needed to further investigation. Our study showed that bevacizumab was a long-term and effective treatment option for the cases with peritumoral edema resistant to glucocorticoid treatment, where the patient had conditions such as severe headache and neurological deficits.
Diffuse axonal injury (DAI), one of the most common and devastating type of traumatic brain injury, is the result of the shear force on axons due to severe rotational acceleration and deceleration. Neurogranin (NRGN) is a postsynaptic protein secreted by excitatory neurons, and synaptic dysfunction can alter extracellular NRGN levels. In this study, we examined NRGN levels in serum and cerebrospinal fluid (CSF) after experimental DAI in terms of their diagnostic value. Experimental DAI was induced using the Marmarou technique in male Wistar albino rats. Serum and CSF NRGN levels of the sham group, one‑hour, six‑hour, 24‑hour, and 72‑hour post‑DAI groups were measured by ELISA method. DAI was verified by staining with hematoxylin‑eosin and β‑amyloid precursor protein in the rat brain samples. While no histopathological and immunohistochemical changes were observed in the early hours of the post‑DAI groups, the staining of the β‑APP visibly increased over time, with positivity being most frequent and intense in the 72‑hour group. It was found that serum NRGN levels were significantly lower in the 6‑hour group than in the sham group. The serum NRGN levels in the 24‑hour group were significantly higher than those in the sham group. This study showed a dichotomy of post‑DAI serum NRGN levels in consecutive time periods. NRGN levels in CSF were higher in the one‑hour group than in the sham group and returned to baseline by 72 hours, although not significantly. Our study provides an impression of serum and CSF NRGN levels in a rat DAI model in consecutive time periods. Further studies are needed to understand the diagnostic value of NRGN.